Scientist Luke Hoeppner, PhD, Receives $50K Award From The American Cancer Society
"Standard therapy for SCLC patients has not substantially improved since the introduction of chemotherapeutic agents over 30 years ago because oncogenic drivers remain poorly understood. Recent advances in immunotherapy have proven effective against some types of SCLC, but immunotherapy is not effective in many cases of SCLC. New strategies to treat small cell lung cancer are urgently needed.”
This year's theme is a unique blend of science and career exploration, offering an enriching experience that emphasizes both professional development and scientific excellence.
The VMTC aims to accelerate the translation of life-changing therapies from bench to bedside in order to provide greater relief and more safe and effective treatment options to patients.
Our mission is to build relationships, foster collaboration, and showcase the latest advancements in bioimaging and correlative techniques.
